Century Therapeutics (IPSC) Operating Expenses (2020 - 2026)

Century Therapeutics (IPSC) has 7 years of Operating Expenses data on file, last reported at $23.7 million in Q1 2026.

• On a quarterly basis, Operating Expenses fell 32.31% year-over-year to $23.7 million in Q1 2026; TTM through Mar 2026 was $115.1 million, a 21.98% decrease from a year earlier, with the FY2025 full-year figure at $126.4 million, down 12.64% from the prior year.
• Operating Expenses for Q1 2026 stood at $23.7 million, up from $20.7 million in the prior quarter.
• Over the last five years, Operating Expenses for IPSC reached as high as $44.0 million in Q4 2023 and fell as low as $20.7 million in Q4 2025.
• Historically, Operating Expenses has averaged $34.3 million across 5 years, with a median of $35.0 million in 2025.
• Across the five-year window, Operating Expenses jumped 113.12% in 2022 and plunged 50.19% in 2025, its largest moves.
• Year by year, Operating Expenses stood at $33.8 million in 2022, then soared by 30.16% to $44.0 million in 2023, then fell by 5.84% to $41.5 million in 2024, then plunged by 50.19% to $20.7 million in 2025, then gained by 14.69% to $23.7 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $23.7 million in Q1 2026, $20.7 million in Q4 2025, and $36.1 million in Q3 2025.